Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Date
2021
Author
Fradet, Yves
Matsubara, Nobuaki
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai
Powles, Thomas
Csoszi, Tibor
ÖZGÜROĞLU, Mustafa
Geczi, Lajos
Cheng, Susanna Y-S
Oudard, Stephane
Vulsteke, Christof
Barrera, Rafael Morales
Metadata
Show full item record
Abstract
Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
URI
http://hdl.handle.net/20.500.12627/173131
https://doi.org/10.1016/s1470-2045(21)00152-2
Collections